Fed. Circ. OKs Myriad's Gene Patents In Light Of Prometheus
The Federal Circuit on Thursday once again held that breast cancer genes isolated by Myriad Genetics Inc. are patent-eligible subject matter, affirming its earlier ruling in the case in light of...To view the full article, register now.
Already a subscriber? Click here to view full article